Patient demographics for patients with IPAH/HPAH and APAH
| Parameter | IPAH/HPAH (n=59) | APAH (n=71) | P value |
| Female, n (%) | 26 (44%) | 43 (60%) | 0.062 |
| Age, years | 10.20±6.34 | 7.77±6.33 | 0.033 |
| Weight, kg | 33.75±24.27 | 29.47±21.14 | 0.286 |
| Height, cm | 123.85±37.85 | 116.88±37.49 | 0.298 |
| Body surface area, m2 | 1.04±0.52 | 0.946±0.49 | 0.307 |
| Treatment at RHC, n (%) | |||
| No treatment | 16 (27%) | 27 (38%) | 0.191 |
| Monotherapy by oral route | 9 (15%) | 15 (13%) | 0.394 |
| Double therapy by oral route | 19 (36%) | 20 (28%) | 0.621 |
| Combination therapy using prostacyclin analogue | 15 (25%) | 9 (13%) | 0.062 |
| Vasoreactivity, n (%) | 15 (25%) | 7 (9%) | 0.018 |
| mRAP, mm Hg | 5.48±2.69 | 6.71±3.29 | 0.022 |
| mPAP, mm Hg | 68.43±41.27 | 82.54±44.22 | 0.087 |
| Systolic RVP, mm Hg | 62.56±11.48 | 58.94±12.20 | 0.082 |
| PVRi, Pa s/m³ | 7.21±7.93 | 8.13±7.01 | 0.489 |
| PCWP, mm Hg | 7.01±3.17 | 9.08±3.28 | 0.0004 |
| RVCI, L/min/m2 | 3.56±0.97 | 4.12±1.65 | 0.045 |
| Heart rate, bpm | 85±19 | 98±26 | 0.0016 |
| Ees/Ea_(Kind) | 1.51±0.49 | 1.50±0.52 | 0.993 |
| Ees/Ea_(Takeuchi) | 0.92±0.68 | 095±0.63 | 0.754 |
Data are expressed as mean values (SD), n (%), unless otherwise noted.
Bold p-values indicate significance.
APAH, associated pulmonary arterial hypertension; Ees/Ea_(Kind), vascular–ventricular coupling ratio Kind method; Ees/Ea_(Takeuchi), vascular–ventricular coupling Takeuchi method; IPAH/HPAH, idiopathic and hereditary pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PCWP, pulmonary capillary wedge pressure; PVRi, indexed pulmonary vascular resistance; RHC, right heart catheterisation; RVCI, right ventricular cardiac index; RVP, right ventricular pressure.